Role of autonomic nervous system for development and suppression of motion sickness in Suncus murinus.
To clarify the role of autonomic nervous function in motion sickness, the effect of agents that act on the autonomic nervous system on the motion stimuli-induced emesis was studied in two strains of Suncus murinus (Jic:SUN-Her and Jic:SUN-Ler) with congenitally different sensitivity to veratrine sulfate. We demonstrated significant differences between the two strains in sensitivity to motion stimuli. Isoproterenol (2.5 mg kg(-1), s.c.) significantly prolonged the latency to the first emetic episode induced by motion stimuli and significantly decreased the number of emetic episodes in Jic:SUN-Her suncus. Hexamethoium (2.0 mg kg(-1), s.c.) tended to shorten the latency in Jic:SUN-Ler. Acetylcholine (1.2 mg kg(-1), s.c.) enhanced the emetic response in Jic:SUN-Ler, but atropine (4.0 mg kg(-1), s.c.) suppressed motion stimuli-induced emetic response in Jic:SUN-Her. These results suggest that the predominance of parasympathetic nervous activity is relevant to the enhancement of motion stimuli-induced emetic response, whereas the predominance of sympathetic nervous activity suppresses motion stimuli-induced emetic response. Norepinephrine (0.8 mg kg(-1), s.c.) enhanced motion stimuli-induced emesis contrary to isoproterenol in Jic:SUN-Ler although both drugs are adrenergic agents. However, atropine pretreatment (4.0 mg kg(-1), s.c.) inhibits norepinephrine-induced emetic response. It was considered that norepinephrine-induced emetic response might be dependent on a secondary increase of parasympathetic nervous activity due to bororeflex. Moreover, the different emetic response in Jic:SUN-Her and Jic:SUN-Ler suncus to motion stimuli and drug administration mentioned above indicated that different participation of autonomic nervous activity and/or afferent information from the baroreceptor in the emetic response may exist between these animal groups.
Uchino
M
M
Department of Comparative Pathophysiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Japan. a80503@mail.ecc.u-tokyo.ac.jp
Ishii
K
K
Kuwahara
M
M
Ebukuro
S
S
Tsubone
H
H
D000109:Acetylcholine / Q000494:pharmacology; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001341:Autonomic Nervous System / Q000187:drug effects / Q000503:physiopathology*; D005730:Ganglionic Blockers / Q000627:therapeutic use*; D018738:Hexamethonium / Q000494:pharmacology; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D009038:Motion; D009041:Motion Sickness / Q000188:drug therapy* / Q000503:physiopathology*; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D012788:Shrews / Q000502:physiology*; D013045:Species Specificity; D014839:Vomiting / Q000517:prevention & control
D000316:Adrenergic alpha-Agonists; D000318:Adrenergic beta-Agonists; D005730:Ganglionic Blockers; D018727:Muscarinic Antagonists; D018738:Hexamethonium; D001285:Atropine; D007545:Isoproterenol; D000109:Acetylcholine; D009638:Norepinephrine